<DOC>
	<DOCNO>NCT02171637</DOCNO>
	<brief_summary>Evaluation maximum Tolerated Dose ( MTD ) , safety , pharmacokinetics , efficacy BIBW 2992 , pharmacodynamic modulation biomarkers , correlation Epidermal Growth Factor Receptor ( EGFR ) Human EGF-like Receptor number 2 ( HER2 ) immunohistochemical status objective tumour response</brief_summary>
	<brief_title>Dose Escalation Study Oral Treatment With BIBW 2992 Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Male female patient confirm diagnosis advance , non resectable / metastatic solid tumor , type historically know express EGFR and/or HER2 , fail conventional treatment , therapy proven efficacy exists , amenable establish form treatment Age 18 year old Life expectancy least three ( 3 ) month Written inform consent give consistent International Conference Harmonization Good Clinical Practice ( ICHGCP ) guideline Eastern Cooperative Oncology Group ( ECOG ) performance score 0 , 1 , 2 Patients must resolution prior chemo , hormone , immuno , radiotherapyrelated toxicity CTC Grade &lt; 1 Patients recover previous surgery Paraffinembedded tumor material must accessible analysis EGFR HER2status . The additional 12 patient recruit MTD also fulfill follow criterion : Measurable tumor deposit ( RECIST : Response Evaluation Criteria Solid Tumors ) one technique ( Xray , CT , MRI ) Active infectious disease Gastrointestinal disorder might interfere absorption study drug chronic diarrhea Serious illness concomitant nononcological disease consider investigator incompatible protocol Brain metastases require therapy base clinical symptom Impaired cardiac leave ventricular function rest ejection fraction CTC Grade ≥ 1 Absolute neutrophil count ( ANC ) less 1500 / mm3 Platelet count less 100 000 / mm3 Bilirubin great 1.5 mg / dl ( &gt; 26 μmol / L , SI unit equivalent ) Aspartate amino transferase ( AST ) / alanine amino transferase ( ALT ) great three time upper limit normal ( related liver metastasis great five time upper limit normal ) Serum creatinine great 1.5 mg / dl ( &gt; 132 μmol / L , SI ( Systeme International ) unit equivalent ) Women men sexually active unwilling use medically acceptable method contraception Pregnancy breastfeed Treatment investigational drug ; chemotherapy , immunotherapy , radiotherapy hormone therapy ( exclude LHRH agonist , hormone take breast cancer , bisphosphonates ) participation another clinical study within past four week start therapy concomitantly study Patients unable comply protocol Active alcohol drug abuse RETREATMENT CRITERIA The patient may eligible retreatment previous course finish . The patient eligible follow criterion meet . Patients clinical sign disease progression Xray , CT MRI do test show progressive disease Cardiac leave ventricular function CTC Grade ≥ 2 time previous course Patients fulfil Exclusion Criteria mention exclusion criterion Day 29 previous course Patients recover doselimiting toxicity ( DLT ) 14 day last administration BIBW 2992 previous course . Recovery define return baseline level CTC Grade 1 , whichever high</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>